1,2-propanediol ditosylate | 100073-30-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,2-propanediol ditosylate
• 英文别名: 1,2-bis-(toluene-4-sulfonyloxy)-propane；1,2-Bis-(toluol-4-sulfonyloxy)-propan；2-(4-Methylphenyl)sulfonyloxypropyl 4-methylbenzenesulfonate
• CAS: 100073-30-1
• 化学式: C₁₇H₂₀O₆S₂
• mdl: MFCD00065150
• 分子量: 384.474
• InChiKey: QSFWYZTZYVIPGD-UHFFFAOYSA-N

物化性质

• 沸点：
  546.8±38.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.294
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,2-propanediol ditosylate 、 mesitylphosphine 在 正丁基锂 作用下， 生成 1-mesityl-2-methylphosphirane
  参考文献：
  名称：

  Synthesis of Trivalent Phosphiranes (Phosphacyclopropanes) Stabilized by Bulky Protecting Groups

  摘要：

  DOI：

  10.1055/s-1985-31181
• 作为产物：
  描述：

  1,2-丙二醇 、 对甲苯磺酰氯 生成 1,2-propanediol ditosylate
  参考文献：
  名称：

  110.二硫醇。第四部分 甲苯对磺酸盐和甲磺酸盐与硫羟乙酸钾的反应：一种制备硫醇的新方法

  摘要：

  DOI：

  10.1039/jr9500000579

文献信息

• Oxetane compound, actinic ray curable composition, ink composition for ink jet recording, and image formation method
  申请人：KONICA MINOLTA MEDICAL & GRAPHIC, INC.

  公开号：US20040252171A1

  公开（公告）日：2004-12-16

  Disclosed is an oxetane compound represented by the following formula (I), (II), (III), (IV) or (V): 1

  揭示了以下式子（I），（II），（III），（IV）或（V）所代表的氧杂环化合物：1
• Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof
  申请人：Li Song

  公开号：US20100179116A1

  公开（公告）日：2010-07-15

  The present invention relates to arene connected polyamine macrocyclic derivatives represented by general formula I, pharmaceutically acceptable salts or hydrates thereof which have anti-HIV activities, in which the definitions of substituents are as defined in the description; to preparation methods of the compounds of formula I; to pharmaceutical compositions containing the compounds of formula I or their pharmaceutically acceptable salts or hydrates; to the use of the compounds of formula I or their pharmaceutically acceptable salts or hydrates for the preparation of a medicament for the treatment and prevention of HIV-associated diseases.

  本发明涉及表示为一般式I的芳香烃连接的多胺大环衍生物、其药学上可接受的盐或水合物，具有抗HIV活性，其中取代基的定义如说明书所定义；本发明还涉及制备式I化合物的方法；含有式I化合物或其药学上可接受的盐或水合物的制药组合物；以及使用式I化合物或其药学上可接受的盐或水合物制备治疗和预防HIV相关疾病的药物。
• COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS
  申请人：Radeke Heike S.

  公开号：US20140328756A1

  公开（公告）日：2014-11-06

  The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.

  本发明涉及用于合成和使用成像剂或其前体的系统、组合物和方法。使用本文所述的方法可以将成像剂前体转化为成像剂。在某些情况下，成像剂富含18F。在某些情况下，成像剂可以用于成像主体的感兴趣区域，包括但不限于心脏、心血管系统、心脏血管、大脑和其他器官。在某些实施例中，提供了用于评估主体部分的灌注和神经支配不匹配的方法和组成物。
• Process for preparing manganese complexes
  申请人：UNILEVER PLC

  公开号：EP0522817A1

  公开（公告）日：1993-01-13

  A process for preparing a dinuclear manganese complex of formula (A) wherein:- Mn represents manganese in the III or IV oxidation state, each X is independently a co-ordinating or bridging species selected from H₂O, O₂⁻, O²⁻, OH⁻, SH⁻, S²⁻, 〉S=O, Cl⁻, N₃⁻, SCN⁻, N³⁻, RCOO⁻, NH₂⁻ and NR₃ where R is hydrogen, alkyl or aryl (optionally substituted); L is a ligand which is an organic molecule containing at least three nitrogen atoms which coordinate to a manganese centre; Z represents the charge of the complex and is an integer which may be positive or negative; Y is a monovalent or multivalent counter-ion leading to charge neutrality, which is dependent upon the charge Z of the complex; and q = z/[charge Y], the process comprising the steps of:- (i) reacting an Mn(II) salt with at least an equivalent amount of a compound comprising the ligand L to form said manganese complex characterised in that the reaction is carried out in a non-aqueous solvent; and (ii) optionally, oxidising the manganese complex formed in step (i) with an oxidising agent.

  一种制备式（A）二核锰络合物的工艺 其中 Mn 代表处于 III 或 IV 氧化态的锰，每个 X 都是独立的配位或桥接物种，选自 H₂O 选自 H₂O、O₂-、O²-、OH-、SH-、S²-、〉S=O、 Cl-、N₃-、SCN-、N³-、RCOO-、NH₂- 和 NR₃，其中 R 是氢、烷基或芳基（任选取代）； L 是配体，是至少含有三个氮原子的有机分子，与锰中心配位； Z 代表络合物的电荷，是一个可正可负的整数； Y 是导致电荷中性的一价或多价反离子，取决于络合物的电荷 Z；以及 q = z/[电荷 Y]，该过程包括以下步骤 (i) 将锰（II）盐与至少等量的包含配体 L 的化合物反应，形成所述锰络合物，其特征在于该反应在非水溶剂中进行；以及 (ii) 可选地，用氧化剂氧化步骤(i)中形成的锰络合物。
• Coating varnish composition and antifouling coating composition
  申请人：HITACHI CHEMICAL CO., LTD.

  公开号：EP0608132A1

  公开（公告）日：1994-07-27

  The invention provides a coating varnish composition comprising (A) a polymer obtained by polymerizing (a) at least one unsaturated acid anhydride and (b) at least one other unsaturated monomer, and (B) at least one additive selected from triazole derivatives, benzothiazole derivatives, thiadiazole derivatives, polyethers and carboxylic acid anhydride derivatives and an antifouling coating composition comprising said coating varnish and an antifouling agent containing a coppercompound as major component. Using such compositions the risks of poisoning associated with organotin copolymers are avoided and there are obtained coatings of a coating consuming property and antifouling performance comparable with those of the organotin copolymers which do not gel even when mixed with a copper compound.

  本发明提供了一种涂料清漆组合物，该组合物包含(A)通过聚合(a)至少一种不饱和酸酐和(b)至少一种其他不饱和单体而得到的聚合物，和(B)至少一种选自三唑衍生物、苯并噻唑衍生物、噻二唑衍生物、聚醚和羧酸酐衍生物的添加剂，以及一种防污涂料组合物，该组合物包含上述涂料清漆和一种以铜化合物为主要成分的防污剂。使用这种组合物可以避免与有机锡共聚物有关的中毒风险，并获得涂层消耗特性和防污性能与有机锡共聚物相当的涂层，即使与铜化合物混合也不会凝胶。